Filing Flows › Health Care › Cumberland Pharmaceuticals (CPIX)
Cumberland Pharmaceuticals (CPIX) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 7, 2026 · Cumberland Pharmaceuticals (CPIX) Q2 2026 earnings results →
Q2 2026 Revenue down 19% year over year to $8.8M · 49¢ of every $1 of revenue lost · operating margin -35.9%
Cumberland Pharmaceuticals made $8.8M in Q2 2026 (-19% Y/Y): Talicia $2.3M, Sancuso $1.8M, Vibativ $1.7M. Operating margin -35.9%, net loss $4.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 7, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $8.8M in Q2 2026, down 19% year over year and down 4% from the previous quarter. Talicia was the largest line at 27% of revenue. Kristalose lost $1.7M year over year (down 61%), 83% of the total change.
Operating costs exceeded revenue by $3.2M, an operating margin of -35.9%. Total costs fell 14% while revenue fell 19%. The fastest-growing cost line was Other operating costs (+104%). The quarter ended with a net loss of $4.3M, wider than the previous quarter's $3.3M loss.
Operating cash flow was $169K (down 80% year over year). Non-cash charges added back $78K of share-based compensation. Working capital and other items added $4.4M. Capital expenditures of $38K left free cash flow of $130K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 7, 2026 | $8.8M | -19% | -35.9% | −$4.3M | $169K |
| Q1 2026 | 10-Q | May 8, 2026 | $9.1M | -22% | -34.3% | −$3.3M | $387K |
| Q4 2025 | 10-K | Mar 9, 2026 | $13.7M | +31% | -10.0% | −$1.4M | $3K |
| Q3 2025 | 10-Q | Nov 7, 2025 | $8.3M | -9% | -23.7% | −$1.9M | $187K |
| Q2 2025 | 10-Q | Aug 8, 2025 | $10.8M | +10% | -6.9% | −$735K | $844K |
| Q1 2025 | 10-Q | May 9, 2025 | $11.7M | +38% | 11.0% | $1.3M | $3.9M |
| Q4 2024 | 10-K | Mar 7, 2025 | $10.4M | +12% | -17.7% | −$1.9M | $1.9M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. ("Cumberland," the "Company," or as used in the context of "we," "us" or "our"), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceuticals. We are dedicated to our mission of working together to provide unique products that improve the quality of patient care. Our primary target markets are hospital acute care, gastroenterology and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be served effectively by relatively small, targeted sales forces. We promote our approved products through our hospital, field and oncology sales divisions in the United States.
In its own words, from its 10-K, filed Mar 9, 2026.
Cumberland Pharmaceuticals against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -19% against the peers' median +7%. Operating margin: -35.9% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CPIX Cumberland Pharmaceuticals | Q2 2026 | $8.8M | -19% | -35.9% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Cumberland Pharmaceuticals 10-Q on SEC EDGAR · CIK 1087294 · Pharmaceutical Preparations
13F: who owns CPIX and who is buying
More on CPIX
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results